Systemic Absorption of Cyclopentolate and Adverse Events After Retinopathy of Prematurity Exams

Autor:	Anita, Mitchell, Richard W, Hall, Stephen W, Erickson, Charlotte, Yates, Scott, Lowery, Howard, Hendrickson
Rok vydání:	2016
Předmět:	Male Mydriatics Gestational Age Mass Spectrometry Drug levels 03 medical and health sciences Cellular and Molecular Neuroscience 0302 clinical medicine Vision Screening 030225 pediatrics Medicine Humans Retinopathy of Prematurity Adverse effect Phenylephrine business.industry Infant Newborn Gestational age Systemic absorption Infant Retinopathy of prematurity medicine.disease Cyclopentolate Sensory Systems Dried blood spot Absorption Physiological Ophthalmology Anesthesia 030221 ophthalmology & optometry Female Ophthalmic Solutions business medicine.drug Chromatography Liquid Follow-Up Studies
Zdroj:	Current eye research. 41(12)
ISSN:	1460-2202
Popis:	Preterm infants undergoing Retinopathy of Prematurity Eye Exams (ROPEE) may experience adverse events, possibly from systemic absorption of cyclopentolate. The purpose of this study was to analyze the association between adverse events and drug levels found in neonates undergoing ROPEE.25 infants were randomized into two groups during routine ROP screening: 5 infants for blood collection before mydriatic drops and 20 for blood collection 1 h after eye drops. Blood was collected onto dried blood spot cards, extracted, and analyzed for cyclopentolate and phenylephrine using liquid chromatography and mass spectrometry. Relationships between drug levels and adverse events were assessed.Cyclopentolate (range 6-53 ng/ml) was observed in 15 of 18 infants, while phenylephrine was not detected. Levels of cyclopentolate were significantly higher in infants who were on oxygen (p = 0.01). There was a significant association between cyclopentolate levels and gastric residuals in tube-fed infants not receiving oxygen (p = 0.01).Cyclopentolate levels varied among preterm infants after ROPEE. Cyclopentolate was positively associated with increased gastric residuals. Underlying medical conditions requiring oxygen administration may affect absorption and metabolism of cyclopentolate. There is a need to predict infants at risk for high blood levels of cyclopentolate in order to prevent or treat adverse events after ROPEE.
Databáze:	OpenAIRE
Externí odkaz:	https://explore.openaire.eu/search/publication?articleId=doi_dedup___::9a74cf74c7687a5742b1c27e05dc875d https://pubmed.ncbi.nlm.nih.gov/29985656 Zobrazit plný text záznamu Plný text ve formátu PDF Plný text ve formátu HTML
Nepřihlášeným uživatelům se plný text nezobrazuje	K zobrazení výsledku je třeba se přihlásit.